Impact of respiratory syncytial virus immunization in older adults: the importance of a valid burden estimation
Guay, C.-A.; Doggui, R.; Fortin, P.; Fortin, E.; Amini, R.; Bemmo, A.; Gilca, R.
Show abstract
IntroductionIn the province of Quebec, Canada, a respiratory syncytial virus (RSV) immunization program restricted to seniors residing in long-term care facilities (LTCF) and those aged [≥]75 years from private senior residences (PSR) was implemented in Fall 2024, with approximately 65% vaccine uptake in the targeted populations. Despite high vaccine effectiveness, the real-world impact of the RSV immunization program on population-level averted hospitalizations and the influence that RSV diagnostic test performance might have remains unknown. This study aimed to evaluate the impact of the first season (2024-25) of the intervention among older adults in Quebec while accounting for laboratory test performance. MethodsA prospective hospital-based surveillance (HospiVir) and health administrative databases were used to assess the intervention impact. Observed to expected approach and before/after ecological design using a difference-in-difference Poisson regression, both accounting for seasonal variations and trends in comparison groups, were used. Hospitalization incidence rate estimates based on hospital-based surveillance were adjusted for the laboratory test performances using Lash equations. ResultsBased on HospiVir, a 49% (95% confidence interval (CI): -80- -5) decrease in RSV-associated hospitalizations was observed among adults aged [≥]75 years residing in PSR. This decrease was 23% (95% CI: -38-66) in the overall population [≥]75 years. A smaller decrease for the overall population [≥]75 years was observed using health administrative data, but it did not reach statistical significance (10%; 95% CI: -7-23). The impact of the immunization program did not change following adjustment for diagnostic test performance, while the absolute burden of RSV-associated hospitalizations varied according to the proportion of RSV test positivity. ConclusionsThe 2024-25 RSV immunization program was associated with an almost 50% reduction in hospitalizations in residents of PSR aged [≥]75 years. The magnitude of this reduction was roughly twofold lower when considering the overall population aged [≥]75 years. Expanding the target population and strengthening vaccine promotion efforts to improve uptake are both essential to enhance the population-level impact of the RSV immunization program.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Unveiling the spectrum of Respiratory Syncytial Virus disease in Adults: from Community to Hospital 96%
- Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2 94%
- Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger than 5 years in Japan, 2011-2022: A database study 93%
Similar papers in this journal
- Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study 94%
- A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a Phase 3 clinical study 94%
- Evaluation of the costs of care for pediatric patients hospitalized for RSV: a retrospective cohort study in Belgium 93%
Similar papers in this journal
- Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States 95%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 94%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada 94%
Similar papers in this journal
- Global seasonal activities of respiratory syncytial virus before the COVID-19 pandemic: a systematic review 93%
- Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI) 92%
- Vaccine-induced antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by delta and omicron variants: a prospective observational cohort study 92%
Similar papers in this journal
- Risk and rates of hospitalisation in young children: a prospective study of a South African birth cohort 91%
- Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis 91%
- Contextualizing future maternal RSV vaccination acceptance and trust among pregnant and lactating women in Kenya: A latent class analysis 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.